Literature DB >> 3817873

Modulation of human monocyte Fc receptor function by surface-adsorbed IgG.

T W Jungi, G von Below, P G Lerch, P J Spaeth.   

Abstract

Fc receptor-mediated phagocytosis was measured with monocytes subjected to various treatments. Monocytes exposed to IgG during their adherence, or after they had adhered to a surface, experienced functional impairment. This was manifested in the requirement of a higher antibody density on target particle for efficient phagocytosis, and in an enhanced susceptibility to inhibition by fluid-phase IgG. The impairment was found to be due to an interaction of IgG adhering to the surface with the Fc receptors. This effect could be induced with monomeric IgG, devoid of IgG aggregates or immune complexes. IgG coatings that resulted in inefficient Clq fixation promoted considerable functional impairment of monocytes within 1 hr. In addition, the prolonged contact of monocytes with polystyrene in the absence of IgG also led to a functional reduction. The study points to a compromised function of phagocytes exposed to artificial surfaces.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3817873      PMCID: PMC1453210     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  Studies of 125I trace labeling of immunoglobulin G by chloramine-T.

Authors:  S Sonoda; M Schlamowitz
Journal:  Immunochemistry       Date:  1970-11

2.  Altered surface distribution of both C3b receptors and Fc receptors on neutrophils induced by anti-C3b receptor or aggregated IgG.

Authors:  R M Jack; D T Fearon
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

3.  Human monocyte chemiluminescence triggered by IgG aggregates. Requirement of phospholipase activation and modulation by Fc receptor ligands.

Authors:  D N Rush; P A Keown
Journal:  Cell Immunol       Date:  1984-08       Impact factor: 4.868

4.  A simple method for counting adherent cells: application to cultured human monocytes, macrophages and multinucleated giant cells.

Authors:  A Nakagawara; C F Nathan
Journal:  J Immunol Methods       Date:  1983-01-28       Impact factor: 2.303

5.  Anticomplementary activity of human immunoglobulin G. I. Mechanism of the artifactual increase in anticomplementary activity of IgG during the assay.

Authors:  S I Miekka; I Gozze
Journal:  Vox Sang       Date:  1975       Impact factor: 2.144

6.  Modulation of Fc receptors of mononuclear phagocytes by immobilized antigen-antibody complexes. Quantitative analysis of the relationship between ligand number and Fc receptor response.

Authors:  J Michl; J C Unkeless; M M Pieczonka; S C Silverstein
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307

7.  An extended C1q-binding assay using lactoperoxidase- and chloramine-T-iodinated C1q. Immediate distinction between immune-aggregate-mediated and non-immune-aggregate-mediated C1q binding.

Authors:  P J Spaeth; A Corvetta; U E Nydegger; M Montroni; R Buetler
Journal:  Scand J Immunol       Date:  1983-10       Impact factor: 3.487

8.  Mouse peritoneal macrophages plated on mannan- and horseradish peroxidase-coated substrates lose the ability to phagocytose by their Fc receptors.

Authors:  S S Sung; R S Nelson; S C Silverstein
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

9.  Murine monoclonal antibodies and human alloantisera specific for HLA inhibit monocyte phagocytosis of anti-D-sensitized human red blood cells.

Authors:  J Neppert; F Marquard; C Mueller-Eckhardt
Journal:  Eur J Immunol       Date:  1985-06       Impact factor: 5.532

10.  Selective phagocytic paralysis induced by immobilized immune complexes.

Authors:  M Rabinovitch; R E Manejias; V Nussenzweig
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

View more
  1 in total

1.  Effect of IgG for intravenous use on Fc receptor-mediated phagocytosis by human monocytes.

Authors:  T W Jungi; M Brcic; P Kuhnert; M O Spycher; F Li; U E Nydegger
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.